BIIB - Biogen Inc.
| Previous Close | 232.31 |
| Open | 232.00 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1000 |
| Day's Range | 232.00 - 237.98 |
| 52 Week Range | 215.78 - 358.41 |
| Volume | 1,688,983 |
| Avg. Volume | 1,444,242 |
| Market Cap | 43.646B |
| Beta (3Y Monthly) | 1.44 |
| PE Ratio (TTM) | 8.82 |
| EPS (TTM) | 26.83 |
| Earnings Date | Oct 22, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 258.33 |
- Zacks
What September Doldrums? Here's Why Stocks Are Moving Higher
From ECB stimulus to trade optimism, all are helping stocks eke out gains. And let's admit that recession may be coming, but it isn't around the corner.
- Zacks
Top 5 ROE Stocks to Profit as Sino-US Trade Tensions Abate
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
- Simply Wall St.
Does Biogen Inc.'s (NASDAQ:BIIB) CEO Pay Matter?
Michel Vounatsos became the CEO of Biogen Inc. (NASDAQ:BIIB) in 2017. First, this article will compare CEO...
- GlobeNewswire
New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum
Data highlight benefits of TYSABRI® (natalizumab) treatment in early multiple sclerosis for achieving NEDA (no evidence of disease activity) and improving disability and.
- GlobeNewswire
New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years
Biogen Inc. (BIIB) announced new data to support the consistent, long-term benefits of treatment with TECFIDERA® (dimethyl fumarate) over 10 years, as well as additional diroximel fumarate data that further characterize the tolerability profile of this investigational oral fumarate for relapsing multiple sclerosis (MS). “Biogen’s new data underscore TECFIDERA’s role as a meaningful long-term therapy option for relapsing MS, with many patients in the study experiencing no relapses or progression in their disability over a 10-year period,” said Alfred Sandrock, Jr., M.D., Ph.D., executive vice president and chief medical officer at Biogen.
- Zacks
Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group
Amgen's (AMGN) novel investigational KRAS inhibitor, AMG 510, for solid tumor shows anti-tumor activity in a larger group of NSCLC patients.
- Zacks
5 Price-to-Book Value Picks for September
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
- Zacks
Novartis Inks Commercialization Deal for Tysabri Biosimilar
Novartis' (NVS) generics unit, Sandoz, inks deal with Polpharma Biologics for a proposed natalizumab biosimilar for the treatment of RRMS.
- Motley Fool
Better Buy: Gilead Sciences vs. Biogen
Which stock wins in a battle between these two big biotechs?
- Zacks
Novartis' (NVS) MS Drug Achieves Goals in Late-Stage Studies
Novartis (NVS) MS drug meets primary and secondary endpoints in late-stage studies.
- Zacks
Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo
Ionis (IONS) out-licenses antisense medicines to Glaxo for treating chronic hepatitis B virus infection. Glaxo exercises its option to in-license the same. Shares fall.
- Zacks
5 ROE Stocks to Profit as Trade War Flip-Flops Rattle Market
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
- Simply Wall St.
Could The Biogen Inc. (NASDAQ:BIIB) Ownership Structure Tell Us Something Useful?
The big shareholder groups in Biogen Inc. (NASDAQ:BIIB) have power over the company. Insiders often own a large chunk...
- GlobeNewswire
Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients
SMA Identified program offers genetic testing for SMA at no charge to individuals in the U.S. CAMBRIDGE, Mass. and SAN FRANCISCO, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (BIIB) and Invitae Corporation (NVTA) today announced that SMA STAT, a new, rapid-turnaround genetic test for spinal muscular atrophy (SMA), will be offered at no charge to individuals in the U.S. as part of the SMA Identified program. The SMA STAT test reduces the time needed for genetic testing to help confirm a definitive diagnosis of SMA from 21 to four days, enabling individuals and physicians to plan and begin treatment earlier for what is often a life-threatening disease.
- Zacks
AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA
AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.
- Zacks
Amgen (AMGN) Soars to 52-Week High, Time to Cash Out?
Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Zacks
Are Investors Undervaluing Biogen (BIIB) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Zacks
Mergers & Acquisitions Take Center Stage in Biotech Industry
Mergers & Acquisitions Take Center Stage in Biotech Industry
- Zacks
Top Ranked Momentum Stocks to Buy for August 12th
Top Ranked Momentum Stocks to Buy for August 12th
- Zacks
5 ROE Stocks to Profit as Trade War Spurs Volatility
ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.
- Zacks
PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y
PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.
- Zacks
Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus
Intercept (ICPT) posts a narrower-than-expected loss in Q2 and surpasses sales estimates.
- Zacks
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
- Thomson Reuters StreetEvents
Edited Transcript of BIIB earnings conference call or presentation 23-Jul-19 12:00pm GMT
Q2 2019 Biogen Inc Earnings Call
